Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.) dominate the field, but many are facing patent expiries during the forecast period, and it will be key to their developers that the subcutaneous forms of these agents capture sufficient market share to offset erosion by IV biosimilar competition. Therapeutics targeting driver mutations such as EGFR and ALK also play a crucial role in the highly biomarker-segmented NSCLC market. These segments will see increasingly fierce competition, especially in the first-line metastatic setting where the interplay of efficacy and tolerability attributes will be key market-share deciders. Expected new market entrants, including highly anticipated antibody-drug conjugates, will further drive competition in the commercially lucrative NSCLC market.

Questions answered

• How will the recent and expected new market entrants shape the treatment landscapes in the various settings and stages (I-IV) of NSCLC?
• Which therapies will dominate the commercially lucrative first-line metastatic NSCLC setting?
• What are the most promising pipeline products, and what will be their likely uptake and patient share in NSCLC?
• What are the NSCLC therapy market’s key drivers and constraints, and how will the market evolve over the forecast period?

Content highlights

• Geographies: United States, EU5, Japan.
• Primary research: Country-specific interviews with thought-leading medical oncologists. Survey data collected for this and other Clarivate research.
• Epidemiology: Diagnosed incidence of NSCLC by country, histology, stage, and line of therapy, segmented into relevant drug-treatable populations.
• Forecast: 10-year, annualized, drug-level sales and patient share of key NSCLC therapies through 2034, segmented by brands / generics and epidemiological subpopulations
• Drug treatments: Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.